企業プロフィール
Oric Pharmaceuticals, Inc. 株価・ニュース・カタリスト
- ティッカー:
- ORIC
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
13.38 USD (-3.53%)
終値
最終更新: 2026年8月17日
789M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ORIC closed down 3.53% at $13.38. No new same-company headline was identified in the current news window.
企業概要
Oncology Resistance Biology
ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments.
Rinzimetostat
Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is being developed with the androgen-receptor inhibitor darolutamide for metastatic castration-resistant prostate cancer after prior abiraterone treatment.
Himalayas-1
Himalayas-1 is the planned global Phase 3 registrational trial of rinzimetostat plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer. Dose-optimization results supported selection of 400 mg once daily as the recommended Phase 3 dose.
Enozertinib
Enozertinib is another clinical-stage ORIC oncology program approaching multiple data updates. The company intends to use these results to determine whether the asset is ready to enter registrational development.
今後のカタリスト
- Initiation of the Phase 3 Himalayas-1 trial expected in the first half of 2026.
- Multiple enozertinib clinical updates expected in the second half of 2026 ahead of a potential registrational trial.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。